The news was announced at the American Stroke Association's International Stroke Conference earlier this month. Research suggests that NimoGel effectively prevented cerebral vasospasm, which is the constriction of blood vessels in the brain, after subarachnoid hemorrhage (SAH). Cerebral vasospasm is a leading cause of permanent brain damage and death after brain injury.
"There is a tremendous unmet medical need in treating brain injuries. Treatments available today are only minimally effective in part because the systemically administered doses that can be tolerated by patients are too low to prevent certain types of delayed complications such as cerebral vasospasm," said R. Loch Macdonald, MD, PhD, Keenan Endowed Chair and Head of the Division of Neurosurgery at St. Michael's Hospital, University of Toronto and Chief Scientific Officer of Edge Therapeutics.
"This preclinical study suggests that it is possible to achieve adequate and sustained concentrations of nimodipine locally and prevent cerebral vasospasm and other potentially deadly complications after brain injury. Based on these encouraging results in a large animal model, further evaluation of NimoGel in human clinical trials is warranted."
Have You Or A Loved One Suffered A Brain Or Spinal Cord Injury?
If you've suffered a brain or spinal cord injury you need to speak with an experienced attorney as soon as possible. Please contact us online or call our office directly at 816.471.5111 to schedule your free consultation.
